Aegerion Pharmaceuticals, Inc. Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference

CAMBRIDGE, Mass., May 29, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that an oral presentation summarizing the final 78-week results from its pivotal Phase III study of lomitapide in patients with adult Homozygous Familial Hypercholesterolemia (HoFH) was presented yesterday at the 80th European Atherosclerosis Society (EAS) Congress in Milan, Italy.